Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

Africa Continues To Strengthen Capacity To Deal With A/H1N1
African countries, with the support of WHO and other development partners, are continuously strengthening their general capacity to deal with cases of Influenza A/H1N1 virus if an outbreak occurs in the region.
generic viagra online
NHS Inpatient And Outpatient Waiting Times Figures, 30 June 2009, UK
The following statistics were released by the Department of Health - Inpatient Waiting Times; Outpatient Waiting Times.
News of the day
WHO Raises Pandemic Alert To Phase 6, Director General Gives Speech
The World Health Organization (WHO) announced it has raised the level of influenza pandemic alert from phase 5 to phase 6, following an
Health Insurance

Phase II Study Of Sunitinib In Men With Advanced Prostate Cancer

UroToday.com - In the Annals of Oncology, Dr. Dror Michaelson and associates reported Phase II data on the efficacy and safety of the tyrosine kinase inhibitor sunitinib in patients with castration-resistant prostate cancer (CRPC). Sunitinib inhibits vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), both elevated in prostate cancer (CaP). Two groups of patients were studied; group A, which was chemotherapy naç¯ve and group B, which had failed docetaxel. The primary endpoint was PSA decline >50% from baseline. Secondary endpoints included objective response rate, safety, tolerability and serum biomarkers. Treatment was in 6-week cycles, consisting of 50mg daily for 4 weeks followed by 2 weeks off. Concurrent treatment with bisphosphonates was permitted. Seventeen men in each group had data available for analysis. Only one patient in group A, and one patient in group B demonstrated a >50% PSA decline. Fourteen of 34 men had some PSA decline and 8 men (34%) had a >30% PSA decline. At 12-week analysis it was noted that radiographic improvements were present in some patients who nevertheless had increasing PSA levels. Based upon not having 2 or more PSA response criteria met, the study enrollment was not continued. Adverse events were primarily grade 1 or 2 and included nausea, fatigue, anorexia, taste disturbance, vomiting, diarrhea and skin rash. Regarding biomarkers, sVEGFR2, PDGFaa, and leptin all decreased but did not correlate with PSA. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR Ann Oncol. 2009 May;20(5):913-20. doi:10.1093/annonc/mdp111 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009